Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
NCT04521114
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
87
Enrollment
INDUSTRY
Sponsor class
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG:
Placebo
DRUG:
leronlimab 700 mg
DRUG:
leronlimab 350 mg
Sponsor
CytoDyn, Inc.